Novosanis has been co-awarded a CASUS grant, which allows to build a next-generation Colli-Pee ® that will be used in a molecular screening solution for cervical cancer.
Novosanis receives grant from Interreg CrossCare to build a next-generation of its unique and patented intradermal drug delivery device, VAX-ID, in collaboration with living labs Happy...
A wrap to an exciting and eventful week! Our Product designer, Alejandra Ríos Cortés, represented Novosanis at the Royal Mission, an initiative led by Princess Astrid of Belgium, to boost...
Today, 4 February, is #worldcancerday. Cervical cancer is one of the most preventable forms of cancer if it’s detected early. HPV urine testing can offer a solution for screening next to...
Timothi Van Mulder will present Novosanis' breakthrough results on the development of a painless injection device for children at 12 th Vaccine Congress in Budapest, Hungary from September...
The Summer Edition of our NewsTalks is live! Read updates on VAX-ID, urine as a sample for detection of breast cancer and the live testing of our next generation Colli-Pee suited for home-...
Novosanis attended IUSTI2018 from June 26 to June 30 in Dublin, Ireland. Our Colli-Pee device suited for first-void urine collection allowing for improved detection of STIs was on display...
Novosanis is teaming up with Voxdale at KfG2018! We are excited to share our research data and showcase our medical device platforms, VAX-ID™ and Colli-Pee™. See you there!
Novosanis
